Windlas Biotech Live Share Price Today, Share Analysis and Chart

About the company - Business Profile

Windlas Biotech Limited is a pharmaceutical formulations company operating primarily in the Contract Development and Manufacturing Organization (CDMO) space. The company focuses on the development and manufacturing of oral solid and liquid formulations, including tablets, capsules, and sachets. Its business model is structured around three main verticals: Generic Formulations CDMO, Trade Generics & Institutional, and Exports. Windlas serves both domestic and international B2B markets, providing complex generic products and health supplements.

Key Points

• Key Facts: Founded in 2001 and headquartered in Dehradun, Uttarakhand, Windlas Biotech Limited is a publicly listed entity on both the NSE (WINDLAS) and BSE (543329).
• Operations and Resources: The company operates five manufacturing facilities, all located in Dehradun, Uttarakhand. As of FY2025, it reported a capacity of 5.4 billion tablets and capsules, 61 million liquid bottles, and 54 million pouches/sachets. A new injectables facility (Plant 5) was commissioned in Q4 FY2024, and work on Plant 6 is ongoing.
• Ownership: The company is promoter-led, with the Windlass family (Ashok Kumar Windlass, Hitesh Windlass, and Manoj Kumar Windlass) holding key management and board positions.
• Market and Significance: Windlas serves approximately 280 customers in its Generic Formulations CDMO vertical. It focuses on high-growth therapeutic segments such as pediatric, geriatric, and acute care.
• Sustainability and Innovation: The company maintains a certified R&D department (DSIR certified). In FY2024, 64% of its generic formulations in the CDMO vertical were classified as complex generics.

Business Model and Financial Performance

Windlas Biotech’s business model leverages its integrated R&D and manufacturing capabilities to provide end-to-end solutions for pharmaceutical brands. It is particularly proficient in managing complex generic formulations and high-volume manufacturing.

Revenue Breakdown (FY2025 Consolidated):

• Generic Formulations CDMO: ₹568.1 crore (75% of total revenue)
• Trade Generics & Institutional: ₹165.7 crore (22% of total revenue)
• Exports: ₹26.5 crore (3% of total revenue)

Geographical Performance: While the majority of revenue is derived from the Indian domestic market via its CDMO and trade generic segments, the company is actively expanding its export footprint, which includes generic medicines and health supplements.

Key Financial Metrics (FY2025):

• Total Revenue: ₹760.3 crore (compared to ₹631 crore in FY2024)
• EBITDA: ₹94.3 crore (12.4% Margin)
• Profit After Tax (PAT): ₹60.8 crore (8.0% Margin)
• Return on Equity (ROE): 25% (Adjusted)
• Return on Capital Employed (ROCE): 27% (Adjusted)

Operational Metrics:

• Employee Count: 1,154 employees (as of FY2024).
• Quality Control Personnel: 161 employees dedicated to quality control.
• Licensed Products: 6,849 products licensed for manufacture.

Strategic Initiatives and Outlook

The company’s current strategy focuses on scaling its injectables business and enhancing its presence in the export market. The commissioning of the injectable facility in FY2024 is a major step toward diversification into sterile formulations. Windlas is also investing in its "Plant 6" expansion to further increase capacity. Future growth is expected to be driven by an increasing shift toward complex generics and the expansion of the Trade Generics brand portfolio, which currently features 583 brands.

References

1. Annual Report May 2025
2. Annual Report May 2024
3. Investor Presentation Feb 2026
4. Investor Presentation Nov 2025